Last update 08 May 2025

RSV 6120/ΔNS2/1030s Vaccine(National Institute of Allergy & Infectious Diseases)

Overview

Basic Info

Drug Type
Prophylactic vaccine
Synonyms-
Target-
Action
stimulants
Mechanism
Immunostimulants
Therapeutic Areas
Infectious Diseases
Active Indication-
Inactive Indication
Respiratory Syncytial Virus Infections
Originator Organization
National Institute of Allergy & Infectious Diseases
Active Organization-
Inactive Organization
National Institute of Allergy & Infectious Diseases
License Organization-
Drug Highest PhaseDiscontinuedPhase 1/2
First Approval Date-
Regulation-
Login to view timeline

Related

1
Clinical Trials associated with RSV 6120/ΔNS2/1030s Vaccine(National Institute of Allergy & Infectious Diseases)
NCT03916185
/ TerminatedPhase 1/2IIT
Randomized Phase I/II Study of the Safety and Immunogenicity of a Single Dose of the Recombinant Live-Attenuated Respiratory Syncytial Virus (RSV) Vaccines RSV ΔNS2/Δ1313/I1314L, RSV 6120/ΔNS2/1030s, RSV 276 or Placebo, Delivered as Nose Drops to RSV-Seronegative Children 6 to 24 Months of Age
100 Clinical Results associated with RSV 6120/ΔNS2/1030s Vaccine(National Institute of Allergy & Infectious Diseases)
Login to view more data
100 Translational Medicine associated with RSV 6120/ΔNS2/1030s Vaccine(National Institute of Allergy & Infectious Diseases)
Login to view more data
100 Patents (Medical) associated with RSV 6120/ΔNS2/1030s Vaccine(National Institute of Allergy & Infectious Diseases)
Login to view more data
100 Deals associated with RSV 6120/ΔNS2/1030s Vaccine(National Institute of Allergy & Infectious Diseases)
Login to view more data

R&D Status

10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Respiratory Syncytial Virus InfectionsPhase 2
United States
National Institute of Allergy & Infectious Diseases
20 Jun 2019
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
NCT03916185 (CTgov)
Phase 1/2
Respiratory Syncytial Virus Infections
67
(RSV ΔNS2/Δ1313/I1314L Vaccine)
klwdfkyyhz(vtxfnnnbky) = svphmzzdat ekbvjzegga (kyibbknurl, vppujpxnus - hfzommpwgl)
View more
-
21 Feb 2025
(RSV 6120/ΔNS2/1030s Vaccine)
klwdfkyyhz(vtxfnnnbky) = ypwceyujpp ekbvjzegga (kyibbknurl, fdfuahnivc - jtyqovzclu)
View more
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
login
or
view full example data
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
login
or
view full example data
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
login
or
view full example data
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
login
or
view full example data
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
login
or
view full example data
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
login
or
view full example data
Understand key drug designations in just a few clicks with Synapse.
AI Agents Built for Biopharma Breakthroughs
Accelerate discovery. Empower decisions. Transform outcomes.
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free